French pharma giant expands neuroscience pipeline with Boston biotech’s microglial disease expertise Sanofi announced its intention to acquire all remaining shares of Vigil Neuroscience for
Strategic deal adds premium implantable lens technology at 51% premium to strengthen refractive surgery position Alcon announced its agreement to acquire STAAR Surgical for approximately
PharmaTher’s KETARx becomes first FDA-approved ketamine formulation for on-label surgical use In a historic regulatory milestone, the FDA approved PharmaTher’s KETARx on August 8, 2025,
Phase 3 trial demonstrates practice-changing survival benefits in muscle-invasive disease Pfizer announced highly positive interim results from a pivotal Phase 3 trial combining its antibody-drug
Major intellectual property resolution clears path for both companies’ mRNA pipelines GlaxoSmithKline reached a landmark settlement in its high-stakes mRNA vaccine intellectual property litigation with
Healthcare policy analysts are projecting potentially significant premium increases of up to 20% for Affordable Care Act (ACA) marketplace plans in 2026, driven by a
The FDA has granted clearance to Nyxoah’s innovative Genio system, a breakthrough hypoglossal nerve stimulation device designed to treat obstructive sleep apnea. This regulatory approval
HeartFlow has made a spectacular public market debut, with shares soaring 47% following the company’s $317 million initial public offering on Nasdaq. The strong market
Pfizer and BioNTech have reached a substantial $740 million settlement agreement with CureVac to resolve a complex patent dispute involving foundational mRNA technology that underpins
The FDA has imposed significant restrictions on Bluebird Bio’s Skysona gene therapy following the emergence of concerning cancer risks in treated patients. This regulatory action
